Table 3 Sample’s characteristics according to the presence of no DM, prediabetes and DM, accessed by OGTT
Glucose at 120 min | P value | |||
|---|---|---|---|---|
<140 mg/dL | 140–200 mg/dL | ≥200 mg/dL | ||
n (%) | 154 (70) | 53 (24.1) | 13 (5.9) | |
Sex [n (%)] | 0.061 | |||
Male | 101 (65.6) | 26 (49.1) | 6 (46.2) | |
Female | 53 (34.4) | 27 (50.9) | 7 (53.8) | |
Age [years, mean (SD)] | 43.4 (10.2) | 50.4 (12.1) | 55 (13.6) | < 0.001 |
Duration of HIV infection [years, median (IR)] | 8 (6) | 7 (6) | 10 (8) | 0.980 |
cART [years, [median (IR)] | 6 (5.3) | 6 (7) | 9 (9) | 0.566 |
Clinical lipodystrophy [n (%)] | 0.148 | |||
Without CL | 78 (50.6) | 24 (45.3) | 3 (23.1) | |
With CL | 76 (49.4) | 29 (54.7) | 10 (76.9) | |
Body Composition [n (%)] | 0.078 | |||
No lipodystrophy | 23 (15.5) | 7 (13.5) | 1 (7.7) | |
Isolated central fat accumulation | 50 (33.8) | 17 (32.7) | 2 (15.4) | |
Lipoatrophy | 45 (30.4) | 11 (21.2) | 2 (15.4) | |
Mixed form of lipodystrophy | 30 (20.3) | 17 (32.7) | 8 (61.5) | |
BMI [(kg/m2), [median (IR)] | 24.5 (5.8) | 25.4 (6.4) | 25.5 (3.3) | |
Waist circumference [cm, median (IR)] | 90.5 (16) | 91 (17.8) | 95 (8.5) | 0.687 |
CD4 cell count [cells/mm3, [median (IR)] | 512.5 (336) | 500 (311) | 456 (509) | 0.569 |
HIV RNA (<50) [n (%)] | 138 (100) | 44 (100) | 10 (100) | |
Hepatitis C co-infection [n (%)] | 47 (30.9) | 15 (28.8) | 2 (16.7) | 0.655 |
CDC clinical categories [n (%)] | 0.252 | |||
A | 90 (58.4) | 24 (45.3) | 5 (38.5) | |
B | 4 (2.6) | 1 (1.9) | 0 (0) | |
C | 60 (39) | 28 (52.8) | 8 (61.5) | |
ART [n (%)] | ||||
IP | 77 (50) | 36 (67.9) | 10 (76.9) | 0.023 |
NNRTI | 82 (53.2) | 17 (32.1) | 3 (23.1) | 0.005 |
NRTI | 148 (96.1) | 51 (96.2) | 11 (84.6) | 0.188 |
HOMA-IR index [median (IR)] | 1.4 (1.5) | 2.4 (2.5) | 1.9 (3.2) | < 0.001 |
QUICKI index [median (IR)] | 0.4 (0.1) | 0.3 (0.1) | 0.4 (0.1) | < 0.001 |
Total cholesterol [mg/dL, median (IR)] | 224 (67) | 224 (79) | 234 (86) | 0.743 |
LDL- cholesterol [mg/dL, median (IR)] | 130 (70) | 135 (66) | 156 (79) | 0.843 |
HDL- cholesterol [mg/dL, median (IR)] | 49 (19) | 44 (20) | 52 (15) | 0.314 |
Triglycerides [mg/dL, median (IR)] | 186 (176.5) | 223 (258.5) | 170 (101) | 0.131 |
Statin use [n (%)] | 31 (20.1) | 9 (17) | 6 (46.2) | 0.072 |
Fibrate use [n (%)] | 43 (27.9) | 21 (39.6) | 1 (7.7) | 0.061 |